Company News

Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4M

Uni-Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships

The four-pillar cultivates new growth engines for high-quality development | Uni-Bio Science Group's 2023 Annual Strategy Conference was successfully held The four-pillar cultivates new growth engines for high-quality development | Uni-Bio Science Group's 2023 Annual Strategy Conference was successfully held

Join hands together and Build up a head of steam | Uni-Bio Science Group's 2023 Annual Marketing Conference was successfully held

Uni-Bio Science's Chairman Won HK Innopreneur Awards – GBA+ Award

2022 Interim Results Pinup® and Boshutai® Generated Remarkable Turnover while Achieving Record High Profit Aim to Build a Highly Commercial-Driven and Specialized R&D Platform

Marketing application of BOGUTAI® (teriparatide injection) has been officially accepted by the China National Medical Products Administration (NMPA)

Uni-Bio Science Group opens Hong Kong research centre,Future R&D focus in four major businesses

Uni-Bio Science Group’s BOSHUTAI® (Acarbose Tablets) successfully selected for Henan thirteen provinces alliance procurement